Results 1 to 10 of about 78,603 (193)

Anti-HSV-1 agents: an update. [PDF]

Front Pharmacol
Herpes simplex virus type I (HSV-1) is a member of the α-herpesvirus subfamily and is capable of causing herpes simplex keratitis, herpes labialis, and herpes simplex encephalitis. HSV-1 is well known for its lytic infections at the primary sites and for establishing latency in the sensory neuronal ganglia, with occasional recurrent infections. To date,
Lv W, Zhou L, Wu J, Cheng J, Duan Y, Qian W.   +5 more
europepmc   +4 more sources

Human lactoferrin but not lysozyme neutralizes HSV-1 and inhibits HSV-1 replication and cell-to-cell spread [PDF]

Virology Journal, 2009
The frequent oral shedding of herpes simplex virus type 1 (HSV-1) in the absence of clinical disease suggests that symptomatic HSV-1 recurrences may be inhibited by the mucosal environment.
Välimaa Hannamari, Tenovuo Jorma, Waris Matti, Hukkanen Veijo   +3 more
doaj   +4 more sources

Protection of Mice by an Apathogenic Strain of HSV-1 Against Lethal Infection by a Pathogenic Strain of HSV-1

Journal of General Virology, 1981
DBA/2 and C57BL/6 mice were infected intraperitoneally with two different strains of herpes simplex virus type 1, HSV-1 ANG and HSV-1 WAL. Unlike HSV-1 WAL, HSV-1 ANG was apathogenic by this mode of infection. Furthermore, infection with HSV-1 ANG protected mice of both inbred strains against infections with lethal doses of pathogenic HSV-1 WAL.
Christoph Schröder, H. Engler, Holger Kirchner   +2 more
openalex   +4 more sources

Bell's palsy and HSV-1 infection [PDF]

Muscle & Nerve, 1999
Christina M. Marra
openalex   +4 more sources

HSV-1 Amplicon Vectors—Simplicity and Versatility [PDF]

Molecular Therapy, 2000
Miguel Sena‐Esteves, Yoshinaga Saeki, Cornel Fraefel, Xandra O. Breakefield   +3 more
openalex   +4 more sources

Epigallocatechin Gallate-Modified Silver Nanoparticles Show Antiviral Activity against Herpes Simplex Type 1 and 2

Viruses, 2023
(1) Background: Epigallocatechin gallate (EGCG) has been recognized as a flavonoid showing antiviral activity against various types of DNA and RNA viruses.
Malgorzata Krzyzowska, Martyna Janicka, Marcin Chodkowski, Magdalena Patrycy, Oliwia Obuch-Woszczatyńska, Emilia Tomaszewska, Katarzyna Ranoszek-Soliwoda, Grzegorz Celichowski, Jaroslaw Grobelny   +8 more
doaj   +1 more source

Application of Environment-Friendly Rhamnolipids against Transmission of Enveloped Viruses Like SARS-CoV2

Viruses, 2021
In the face of new emerging respiratory viruses, such as SARS-CoV2, vaccines and drug therapies are not immediately available to curb the spread of infection.
Ling Jin, Wendy Black, Teresa Sawyer
doaj   +1 more source

Seroprevalence of antibodies to herpes simplex virus 1 and 2 in patients with HIV positive from Ebonyi State, Nigeria: a cross-sectional study

BMJ Open, 2023
Objectives To assess the seroprevalence of herpes simplex virus (HSV) types 1 and 2 in patients infected with HIV in Nigeria.Design Cross-sectional design from January to June 2019.Setting Federal Teaching Hospital, Ebonyi State, Nigeria.Participants A ...
Euslar Nnenna Onu, Uchechukwu Onyeukwu Ekuma, Hawraa K Judi, Ogbonnaya Ogbu, Nworie Okoro, Gloria C Ajugwo, Sousan Akrami, Chukwudum S Okoli, Chioma Ngozi Anyanwu, Morteza Saki, Peter Anyigor Edeh   +10 more
doaj   +1 more source

Detection of herpes simplex virus in oral tongue squamous cell carcinoma

Frontiers in Pharmacology, 2023
Introduction: Oral tongue squamous cell carcinoma (OTSCC) is the most common cancer of the oral cavity. Contradictory results have been observed on the involvement of herpes simplex virus 1 (HSV-1) in oral squamous cell carcinomas.
Tiina Koivikko, Tiina Koivikko, Priscila Campioni Rodrigues, Priscila Campioni Rodrigues, Mari Vehviläinen, Petra Hyvönen, Petra Hyvönen, Elias Sundquist, Elias Sundquist, Riikka K. Arffman, Riikka K. Arffman, Ahmed Al-Samadi, Hanna Välimaa, Hanna Välimaa, Hanna Välimaa, Tuula Salo, Tuula Salo, Tuula Salo, Tuula Salo, Maija Risteli, Maija Risteli   +20 more
doaj   +1 more source

Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1 [PDF]

Gene Therapy, 1997
Herpes simplex virus type-1 (HSV-1) has been used for gene delivery in the nervous system for the treatment of brain tumors and other neurological diseases. In most protocols, recombinant viruses containing the gene of interest are directly injected into the brain.
J Guo, Q Wang, William Jia
openaire   +3 more sources